Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CALITHERA BIOSCIENCES, INC.

(CALA)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
2.860 USD   -2.39%
09/06Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
AQ
08/30North American Morning Briefing: Dow Futures Jump -2-
DJ
08/29HC Wainwright Upgrades Calithera Biosciences to Buy From Neutral; Price Target is $8
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
3.28(c) 2.89(c) 2.775(c) 2.93(c) 2.86(c) Last
16 017 110 857 19 527 35 783 10 580 Volume
-3.81% -11.89% -3.98% +5.59% -2.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -38,6 M - -
Net cash position 2022 24,0 M - -
P/E ratio 2022 -0,64x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -43,5 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,47x
Yield 2023 -
Capitalization 13,9 M 13,9 M -
EV / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 63
Free-Float 98,8%
More Financials
Company
Calithera Biosciences, Inc. is a clinical-stage, precision oncology biopharmaceutical company. The Company is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The Company is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Ratings of Calithera Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about CALITHERA BIOSCIENCES, INC.
09/06Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
AQ
08/30North American Morning Briefing: Dow Futures Jump -2-
DJ
08/29HC Wainwright Upgrades Calithera Biosciences to Buy From Neutral; Price Target is $8
MT
08/16Calithera : Q2 Earnings Snapshot
AQ
08/16CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/15Calithera Biosciences : Reports Second Quarter 2022 Financial Results and Recent Highlight..
PU
08/15Calithera Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Mon..
CI
08/15Transcript : Calithera Biosciences, Inc., Q2 2022 Earnings Call, Aug 15, 2022
CI
08/15Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highligh..
AQ
08/08Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August..
AQ
07/14Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs..
AQ
07/13Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs..
AQ
07/13Calithera Biosciences, Inc. Shares Progress in Sapanisertib and Mivavotinib Clinical Pr..
CI
07/06Calithera Biosciences Enrolls First Patient in Phase 2 Lung Cancer Trial; Shares Rise A..
MT
07/06Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sap..
AQ
More news
News in other languages on CALITHERA BIOSCIENCES, INC.
08/15Calithera Biosciences, Inc. annonce ses résultats pour le deuxième trimestre et le seme..
07/13Calithera Biosciences, Inc. partage les progrès des programmes cliniques Sapanisertib e..
07/06Calithera Biosciences recrute son premier patient dans le cadre d'un essai de phase 2 s..
07/06Calithera Biosciences annonce que le premier patient s'est inscrit à l'essai clinique d..
06/23Calithera Biosciences commence le recrutement pour l'essai de phase 2 du mivavotinib da..
More news
Analyst Recommendations on CALITHERA BIOSCIENCES, INC.
More recommendations
Chart CALITHERA BIOSCIENCES, INC.
Duration : Period :
Calithera Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CALITHERA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,86 $
Average target price 15,75 $
Spread / Average Target 451%
EPS Revisions
Managers and Directors
Susan M. Molineaux President, CEO, CFO & Director
Stephanie Wong CFO, Secretary & Chief Accounting Officer
Francesco Parlati Vice President-Research
Susan B Demo Senior Vice President-R&D Operations
Emil T. Kuriakose Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CALITHERA BIOSCIENCES, INC.-78.50%14
JOHNSON & JOHNSON-3.58%435 655
ELI LILLY AND COMPANY11.32%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.33%245 989